title: Should we start all patients with diabetic retinopathy on fenofibrates?
abstract: There remains a need for strategies that are effective in preventing diabetic retinopathy (DR) or slowing down its progression, which is safe, well-tolerated, and more effective, have a lower risk profile, easy to perform, have more predictable results with less morbidity than the current regimens. Physicians caring for diabetic patients not only need to maximize glycemic control, but also closely monitor and treat other systemic conditions. The consistency of clinical data from the fenofibrate studies showed consistent beneficial effects with fenofibrate in slowing the progression of DR. They demonstrated significant benefit on micro-vascular (i.e., retinopathy and nephropathy) outcome, possibly independent of lipid levels. Can we combine the effectiveness of the current standard procedures with the prevention and slowing down of progression of DR that fenofibrates can offer? Knowledge of the primary mode of action of fenofibrate will be useful for both physicians and patients in determining how best to use this drug as an adjunct in the management of DR and ultimately facilitating the translation of clinical trial data to clinical practice.
authors: Department of Ophthalmology, Christian Medical College, Ludhiana, Punjab, India.
authors: Jacob
authors: J
authors: Koshy
authors: Jency M
authors: JM
authors: Koshy
authors: Satish
authors: S
authors: Thomas
authors: Gurvinder
authors: G
authors: Kaur
authors: Thomas
authors: T
authors: Mathew
mesh_terms: D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*
chemical_list: D000960:Hypolipidemic Agents; D011345:Fenofibrate
keywords: Diabetic retinopathy; fenofi brates; medical management